ERBB2 and breast cancer: A phase II trial is currently underway to investigate ZW25’s effectiveness when combined with palbociclib and fulvestrant, aiming to provide chemotherapy-free options for advanced HR-positive/HER2-positive BC cases [NCT04224272] [78].